



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/412,100	10/04/1999	ZHONG-MIN WEI	21829/31-(EB)	9211

7590 02/12/2004

MICHAEL L GOLDMAN
NIXON PEABODY LLP
CLINTON SQUARE
P O BOX 31051
ROCHESTER, NY 14603-1051

EXAMINER

ROBINSON, HOPE A

ART UNIT PAPER NUMBER

1653

DATE MAILED: 02/12/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Notice of Allowability

Application No.

09/412,100

Examiner

Hope A. Robinson

Applicant(s)

WEI ET AL.

Art Unit

1653

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 11/24/03.
2. ☒ The allowed claim(s) is/are 1,5,7,9,30-38 and 48-57.
3. ☒ The drawings filed on 10/04/99 are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.


5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
 6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____
4. ☐ Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☐ Interview Summary (PTO-413),
Paper No./Mail Date _____
7. ☐ Examiner's Amendment/Comment
8. ☐ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____

Christopher S. F. Low
CHRISTOPHER S. F. LOW
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN	530	350



Harpin fragments derived from HrpN of *Erwinia amylovora*

FIGURE 1

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN	530	350

1; 5'-GGGAATTCATATGAGTCTGAATACAAGTGGG-3'
 76; 5'-GGGAATTCATATGGGCGGTGGCTTAGGCGGT-3'
 99; 5'-GGCATATGTCGAACGCGCTGAACGATATG-3'
 105; 5'-GGGAATTCATATGTTAGGCGGTTTCGCTGAAC-3'
 110; 5'-GGCATATGCTGAACACGCTGGGCTCGAAA-3'
 137; 5'-GGCATATGTCAACGTCCCAAACGACGAT-3'
 150; 5'-GGCATATGTCCACCTCAGACTCCAGCG-3'
 169; 5'-GGGAATTCATATGCAAAGCCTGTTTGGTGTATGGG-3'
 1210; 5'-GGGAATTCATATGGGTAATGGTCTGAGCAAG-3'
 1267; 5'-GGGAATTCATATGAAAGCGGGCATTGAGGCG-3'
 1343; 5'-GGGAATTCATATGACACCAGCCAGTATGGAGCAG-3'
 175; 5'-GCAAGCTTAACAGCCCACCACCGCCCATCAT-3'
 1104; 5'-GCAAGCTTAAATCGTTCAGCGCGTTCGACAG-3'
 1168; 5'-GCAAGCTTAAATATCTCGCTGAACATCTTCAGCAG-3'
 1180; 5'-GCAAGCTTAAAGGTGCCATCTTGCCCATCAC-3'
 1204; 5'-GCAAGCTTAAATCAGTGACTCCTTTTTTATAGGC-3'
 1209; 5'-GCAAGCTTAAACAGGCCCGACAGCGCATCAGT-3'
 1266; 5'-GCAAGCTTAAACCGATACCGGTACCCACGGC-3'
 1342; 5'-GCAAGCTTAAATCCGTCGTCATCTGGCTTGCTCAG-3'
 1403; 5'-GCAAGCTTAAAGCCGCGCCAGCTTG-3'

Oligonucleotide primers used for the construction of the subclones of *Erwinia amylovora* hrpN.

FIGURE 2

09412100.100495